Page 21234..1020..»

Healthy Extracts Introduces Ultimate Brain Nutrients RELIEF™ for Migraine Sufferers, a Breakthrough Natural Treatment Clinically Shown to Reduce…

By Dr. Matthew Watson

LAS VEGAS, Aug. 31, 2021 (GLOBE NEWSWIRE) -- Healthy Extracts Inc. (OTCQB: HYEX), a leading innovator of clinically proven plant-based products for heart and brain health, has launched Ultimate Brain Nutrients RELIEF™, a proprietary, patent-pending natural formulation that provides relief from symptoms often associated with migraine headaches, while increasing brain and cognitive activation.

See more here:
Healthy Extracts Introduces Ultimate Brain Nutrients RELIEF™ for Migraine Sufferers, a Breakthrough Natural Treatment Clinically Shown to Reduce...

To Read More: Healthy Extracts Introduces Ultimate Brain Nutrients RELIEF™ for Migraine Sufferers, a Breakthrough Natural Treatment Clinically Shown to Reduce…
categoriaGlobal News Feed commentoComments Off on Healthy Extracts Introduces Ultimate Brain Nutrients RELIEF™ for Migraine Sufferers, a Breakthrough Natural Treatment Clinically Shown to Reduce… | dataSeptember 1st, 2021
Read All

Genetic Technologies Reports FY21 Results as it Turns the Corner on its Commercialization Strategy

By Dr. Matthew Watson

Company to present at H.C. Wainwright 23rd Annual Global Investment Conference taking place virtually September 13-15, 2021 Company to present at H.C. Wainwright 23rd Annual Global Investment Conference taking place virtually September 13-15, 2021

Go here to see the original:
Genetic Technologies Reports FY21 Results as it Turns the Corner on its Commercialization Strategy

To Read More: Genetic Technologies Reports FY21 Results as it Turns the Corner on its Commercialization Strategy
categoriaGlobal News Feed commentoComments Off on Genetic Technologies Reports FY21 Results as it Turns the Corner on its Commercialization Strategy | dataSeptember 1st, 2021
Read All

XORTX Announces New Clinical Advisory Board Member

By Dr. Matthew Watson

CALGARY, Alberta, Aug. 31, 2021 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (CSE:XRX) (OTCQB:XRTXF), a biotechnology company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the addition of one new member to the Company’s clinical advisory board, Dr. Charles Edelstein.

Read this article:
XORTX Announces New Clinical Advisory Board Member

To Read More: XORTX Announces New Clinical Advisory Board Member
categoriaGlobal News Feed commentoComments Off on XORTX Announces New Clinical Advisory Board Member | dataSeptember 1st, 2021
Read All

Total number of shares and voting rights in Zealand Pharma at August 31, 2021

By Dr. Matthew Watson

Company announcement – No. 54 / 2021

See the article here:
Total number of shares and voting rights in Zealand Pharma at August 31, 2021

To Read More: Total number of shares and voting rights in Zealand Pharma at August 31, 2021
categoriaGlobal News Feed commentoComments Off on Total number of shares and voting rights in Zealand Pharma at August 31, 2021 | dataSeptember 1st, 2021
Read All

Nabriva Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

By Dr. Matthew Watson

DUBLIN, Ireland and FORT WASHINGTON, Pa., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Officer at Nabriva, will provide a company overview and business update at the H.C. Wainwright 23rd Annual Virtual Global Investment Conference. The presentation will be available on-demand starting Monday, September 13, at 7:00 A.M. (ET).

Go here to read the rest:
Nabriva Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

To Read More: Nabriva Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
categoriaGlobal News Feed commentoComments Off on Nabriva Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference | dataSeptember 1st, 2021
Read All

Zealand Pharma to Participate in Goldman Sachs 11th Annual Biotech Symposium

By Dr. Matthew Watson

Company announcement – No. 55 / 2021

Link:
Zealand Pharma to Participate in Goldman Sachs 11th Annual Biotech Symposium

To Read More: Zealand Pharma to Participate in Goldman Sachs 11th Annual Biotech Symposium
categoriaGlobal News Feed commentoComments Off on Zealand Pharma to Participate in Goldman Sachs 11th Annual Biotech Symposium | dataSeptember 1st, 2021
Read All

Connect Biopharma Provides Business Update and Reports First Half 2021 Financial Results

By Dr. Matthew Watson

- On Track to Report CBP-201 Phase 2B Top-Line Data Evaluating Moderate-to-Severe Atopic Dermatitis (AD) in Q4 of 2021 -

Here is the original post:
Connect Biopharma Provides Business Update and Reports First Half 2021 Financial Results

To Read More: Connect Biopharma Provides Business Update and Reports First Half 2021 Financial Results
categoriaGlobal News Feed commentoComments Off on Connect Biopharma Provides Business Update and Reports First Half 2021 Financial Results | dataSeptember 1st, 2021
Read All

Histogen to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

By Dr. Matthew Watson

SAN DIEGO, Aug. 31, 2021 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today announced that Richard W. Pascoe, President and Chief Executive Officer of Histogen, will present at the H.C. Wainwright 23rd Annual Global Investment Conference.

More here:
Histogen to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

To Read More: Histogen to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
categoriaGlobal News Feed commentoComments Off on Histogen to Present at the H.C. Wainwright 23rd Annual Global Investment Conference | dataSeptember 1st, 2021
Read All

10x Genomics to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

By Dr. Matthew Watson

PLEASANTON, Calif., Aug. 31, 2021 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (Nasdaq: TXG), today announced the company will be participating in the Morgan Stanley 19th Annual Global Healthcare Conference.

See more here:
10x Genomics to Present at the Morgan Stanley 19th Annual Global Healthcare Conference

To Read More: 10x Genomics to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
categoriaGlobal News Feed commentoComments Off on 10x Genomics to Present at the Morgan Stanley 19th Annual Global Healthcare Conference | dataSeptember 1st, 2021
Read All

Certara to Participate in Upcoming Investor Conferences

By Dr. Matthew Watson

PRINCETON, N.J., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Company management will participate in a fireside chat at the following virtual investor conferences:

Follow this link:
Certara to Participate in Upcoming Investor Conferences

To Read More: Certara to Participate in Upcoming Investor Conferences
categoriaGlobal News Feed commentoComments Off on Certara to Participate in Upcoming Investor Conferences | dataSeptember 1st, 2021
Read All

World-first agreement between Novartis and the NHS enables broad and rapid access to first-in-class cholesterol-lowering medicine Leqvio®…

By Dr. Matthew Watson

Basel, September 01, 2021 — Novartis has reached a commercial agreement with the NHS in England as part of a collaboration to pioneer a first-of-its-kind population health management approach to address elevated LDL-C in eligible patients with ASCVD across England.

Here is the original post:
World-first agreement between Novartis and the NHS enables broad and rapid access to first-in-class cholesterol-lowering medicine Leqvio®...

To Read More: World-first agreement between Novartis and the NHS enables broad and rapid access to first-in-class cholesterol-lowering medicine Leqvio®…
categoriaGlobal News Feed commentoComments Off on World-first agreement between Novartis and the NHS enables broad and rapid access to first-in-class cholesterol-lowering medicine Leqvio®… | dataSeptember 1st, 2021
Read All

Recording of the 6 months 2021 Investor Conference Webinar

By Dr. Matthew Watson

On August 31, 2021 JSC Olainfarm organized its Investor Conference Webinar. During the webinar J?nis Buks, the chairman of the Management Board and J?nis Leimanis, member of the Management Board analyzed the financial results of 6 months 2021 and informed about other recent activities within the company.

See the original post here:
Recording of the 6 months 2021 Investor Conference Webinar

To Read More: Recording of the 6 months 2021 Investor Conference Webinar
categoriaGlobal News Feed commentoComments Off on Recording of the 6 months 2021 Investor Conference Webinar | dataSeptember 1st, 2021
Read All

Chronic Diseases Is Expected To Have Positive Impact On Stem Cell Characterization Kits Market Deman – PharmiWeb.com

By daniellenierenberg

Stem cell characterization kitst Market size is done based on a triangulation methodology that is primarily based on experimental modelling approaches such as patient-level data or disease epidemiology for any key indications , number of procedures and install base analysis for any equipment to obtain precise market estimations for the base year as well as in historic data analysis.

Bottom-up approach is always used to obtain Stem cell characterization kits insightful data for the specific country/regions. The country specific data is again analyzed to derive data at a global level.

Market Overview:-

Stem cells are biological cells that can be converted into specific type of cells as per the bodys requirement. Stem cells are of two types, i.e., adult stem cells and embryonic stem cells. Stem cells can be used to treat various diseases such as cancer, neurodegenerative disorder, cardiovascular disorder and tissue regeneration. Stem cell characterization is the initial step for stem cell research.

Stem cell characterization kit is required to understand the utility of the stem cells in downstream experiments and to confirm the pluripotency of the stem cell.The growth of the stem cell characterization kits market is expected to be being fuelled by government funding for stem cell research.

To Remain Ahead Of Your Competitors, Request for Brochure https://www.factmr.com/connectus/sample?flag=B&rep_id=2691

Fact.MR, a leading authority on market research brings original, in-depth, and insightful reports to investors On Stem Cell Characterization Kits Market Sales & Demand. Fact.MRs report will highlight various growth forecasts, key trends, and notable segments ripe for upcoming investments.

Key Parameters analyzed while estimating the Stem Cell Characterization Kits market include:

Overall Population by age group/Prevalence or Incidence of any disease/Treatment Seeking Rate/Dosage pattern/Average duration of treatment/Overall treatment cost and Reimbursement are considered.

Overall Population/Prevalence or Incidence of disease/treatment seeking rate/ average duration of the treatment/average number of devices used per patient / average number of procedure per device/ average selling price per device/reimbursement are considered.

Number of Healthcare facilities (Hospitals/Ambulatory Surgical Centers/Clinics etc.)

Average number of devices installed per facilities/ lifespan of the devices/replacement rate of the equipment/new sales of the equipment per year/average selling price per equipment are considered.

Extensive rounds of primary and a comprehensive secondary research have been leveraged by the analysts to arrive at various estimations and projections for Sales & Demand of Stem Cell Characterization Kits, its market share, production footprint, current launches, agreements, ongoing R&D projects, and market strategies.

SWOT analysis has been performed in the Sales study to investigate the strengths, weaknesses, opportunities and threats of each player, both at global and regional levels

Company share analysis is used to derive the size of the global Stem Cell Characterization Kits market. As well as a study of the revenues of companies for the last several years also provides the base for forecasting the market size and its Sales growth rate.

This study offers an overview of the existing market trends, metrics, drivers, and restrictions and also offers a point of view for important segments. The report also tracks product and services demand growth forecasts for the market.

Based on type of stem cell, the stem cell characterization kits market is segmented into:

Based on application, the stem cell characterization kits market is segmented into:

Based on end user, the stem cell characterization kits market is segmented into:

North America and Europe are expected to witness significant growth in the global stem cell characterization kit market over the forecast period. This is owing to presence of key manufacturers and researchers of stem cell based therapies in these regions. Moreover, manufacturers such as ThermoFisher Scientific, and Becton Dickinson providing stem cell assays are present in North America region.

Asia Pacific is expected to show significant growth in the stem cell characterization kit market over the forecast period, as researchers from China and Japan are working on stem cell based therapies. For instance, in 2017, clinical trials of embryonic stem cells were launched in China for Parkinsons disease.

The Stem Cell Characterization Kits Sales study analyzes crucial trends that are currently determining the growth of Stem Cell Characterization Kits Market.

There is also to the study approach a detailed segmental review. The report mentions growth parameters in the regional markets along with major players dominating the regional growth.

The Key trends Analysis of Stem Cell Characterization Kits also provides dynamics that are responsible for influencing thefuture Sales and Demand of Stem Cell Characterization Kits marketover the forecast period.

Request Customized Report as Per Your Requirementshttps://www.factmr.com/connectus/sample?flag=RC&rep_id=2691

The report covers following Stem Cell Characterization Kits Market insights and assessment that are helpful for all participants involved in the Stem Cell Characterization Kits market:

NOTE:Our team are studying Covid19 and its impact on the Sales growth of Stem Cell Characterization Kits market and where necessary we will consider the Covid-19 footmark for better analysis of the market Demand and industries outlook. Contact us cogently for more detailed information.

Further, the Stem Cell Characterization Kits market Survey report emphasizes the adoption pattern And Demand of Stem Cell Characterization Kits Market across various industries.

The Stem Cell Characterization Kits Sales study offers a comprehensive analysis on diverse features including production capacities, Stem Cell Characterization Kits demand, product developments, Stem Cell Characterization Kits revenue generation and Stem Cell Characterization Kits Market Outlook across the globe.

Competitive Landscape Analysis On Stem Cell Characterization KitsMarket:

In this report, leading market participants involved in the manufacturing of Stem Cell Characterization Kits are covered. Analysis regarding their product portfolio, key financials such as market shares and sales, SWOT analysis and key strategies are included in this report. To provide decision-makers with credible insights on their competitive landscape, the Stem Cell Characterization Kits industry research report includes detailed market competitive landscape analysis.

Some of the key participants in the global Stem Cell Characterization Kits Market include :

Examples of some of the key participants in the stem cell characterization kits market identified across the value chain include Merck KGaA, Celprogen, Inc., Creative Bioarray, Thermo Fisher Scientific Inc., BD Biosciences, R&D Systems, Inc., System Biosciences, Cosmo Bio USA, BioCat GmbH, and DS Pharma Biomedical Co., Ltd.

Enquiry Before Buying https://www.factmr.com/connectus/sample?flag=EB&rep_id=2691

After glancing through the report on globalStem Cell Characterization Kits market Demand, readers will get valuable insight into the following:

The Survey report highlights the growth factors and entry barriers for the key players and talks about the new trends emerging in the globalStem Cell Characterization Kitsmarket.

In addition to this, the study sheds light on changing market size, revenue growth, and share of important product segments. Analysts at Fact.MR give prominent data on recent technological developments and product developments in the Stem Cell Characterization Kits Demand during the assessment period.

A comprehensive estimate on Demand of Stem Cell Characterization Kits market has been provided through an optimistic scenario as well as a conservative scenario, taking into account the sales of Stem Cell Characterization Kits market during the forecast period. Price point comparison by region with global average price is also considered in the study.

Market Snapshot

The rising prevalence of cancer, cardiovascular disorders and neurodegenerative diseases and the role of stem cell therapy in treating these diseases is projected to drive the growth of stem cell characterization kit market.

As per the American Cancer Society, in 2017 cancer accounted around 1 out of 4 deaths in the U.S. and was the second most common cause of deaths in the U.S.

Stem cell therapy and stem cell transplant has huge potential to treat such chronic diseases, which is expected to have a positive impact on the growth of the stem cell characterization kits market.

Stem cell transplant is useful for the treatment of spinal cord injury, stroke, and Alzheimers disease, which is expected to fuel the adoption of stem cell characterization kits over the forecast period.

The Stem Cell Agency, California, is working on the development of new stem cell-based therapies for chronic diseases such as cancer and rare diseases, where stem cell characterization kits are primarily required.

Stem cell characterization kit is also required to identify the appropriate stem cells for the treatment of -Thalassemia. Due to the increasing research and study on stem cells, the stem cell characterization kit market is expected to witness significant growth over the forecast period.

The role of stem cell characterization kit is very important because if the stem cells are not characterized properly into required adult cell type, transplanted stem cells may revert back to teratomas and there is a possibility of transplant rejection. This is expected to influence the growth of the stem cell characterization kit market.

More Related Reports By Fact.MR On Healthcare Domain :

Veterinary Endodontics Market Veterinary Endodontics Market Forecast, Trend Analysis & Competition Tracking Global Review 202Artificial Eyes to 203Artificial Eyes

Hemorrhoids Treatment Device Market Hemorrhoids Treatment Devices Market Forecast, Trend, Analysis & Competition Tracking Global Market Insights 202Artificial Eyes to 203Artificial Eyes

About Fact.MR

Market research and consulting agency with a difference! Thats why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to us with your goals, and well be an able research partner.

Contact:US Sales Office :11140 Rockville PikeSuite 400Rockville, MD 20852United StatesTel: +1 (628) 251-1583E-Mail:sales@factmr.com

Corporate Headquarter:Unit No: AU-01-H Gold Tower (AU),Plot No: JLT-PH1-I3A,Jumeirah Lakes Towers,Dubai, United Arab Emirates

Visit Our Website:https://www.factmr.com

Read the original post:
Chronic Diseases Is Expected To Have Positive Impact On Stem Cell Characterization Kits Market Deman - PharmiWeb.com

To Read More: Chronic Diseases Is Expected To Have Positive Impact On Stem Cell Characterization Kits Market Deman – PharmiWeb.com
categoriaSpinal Cord Stem Cells commentoComments Off on Chronic Diseases Is Expected To Have Positive Impact On Stem Cell Characterization Kits Market Deman – PharmiWeb.com | dataSeptember 1st, 2021
Read All

Lab-Grown Stem Cell ‘Mini Brains’ Just Developed Eyes – Interesting Engineering

By daniellenierenberg

Researchers at the University Hospital Dusseldorf in Germany have grown primitive eye structures on brain organoids that they had made in their lab. The growth of eye structures in the lab mirrored the one that occurs in the embryo and will help us understand how eyes develop.

The human brain is a fascinating organ and an inspiration for omputer processor developerstoo. However, studying the human brain is not that easy. It is locked up inside the skull for its active period and available for analysis only after its stops to function. Most brain development also occurs quite early in life, leaving little scope for an investigation into its development and workings. Scientists have, therefore, turned to organoids, three-dimensional tissues that can be observed in the petri-dish, to improve our understanding of the brain.

Modern research methods allow us to extract skin or blood cells from an individual and then reprogram them into stem cells. Called induced pluripotent stem cells (iPSCs), these stem cells are capable of developing into any cell type in the body. Scientists carefully modify the nutritional medium they grow in to convert them into desired cell types, even making miniaturized brain cells, if needed.

Neuroscientist Jay Gopalakrishnan at University Hospital Dusseldorf and his team of researchers are interested in studying diseases of the eye. To understand, how these diseases occur in the first place, they need to understand the process of eye development. Other researchers had previously, used iPSCs to develop optic cups, structures that lead to the development of the retina - the light-sensitive layer of cells in the eye.

The retina plays an important role in the eye. It converts the light it receives into neural signals that it transmits to the brain using the optical nerve. The brain then analyses the signals, which in common terms is called 'sight'. Since the retina works closely with the brain, Gopalkrishnan and his team decided to grow the optic cups on brain cells, that were sourced from iPSCs.

Using samples from four iPSC donors, the team first made the brain organoids and then modified its growth media to induce the formation of optic cups.These cups on mini brains not only contained retinal cells but also developed lens and corneal tissue and demonstrated connections to the brain cells. During embryonic development, the retinal cells reach out to the brain but this was never demonstrated in the lab before, until this work.

The optic cups appeared as early as 30 days into the brain development and became distinctly visible by 50 days. The timeline of the development mimicked the one that occurs inside the human embryo. Out of the 314 brain organoids that the team made, almost 73 percent developed optic cups. The study was published in Stem Cell.

Our work highlights the remarkable ability of brain organoids to generate primitive sensory structures that are light sensitive and harbor cell types similar to those found in the body, Gopalkrishnan said in a press release. For future studies, the team wants to increase the viability of the optic cups to help them study diseases of the retina.

View post:
Lab-Grown Stem Cell 'Mini Brains' Just Developed Eyes - Interesting Engineering

To Read More: Lab-Grown Stem Cell ‘Mini Brains’ Just Developed Eyes – Interesting Engineering
categoriaSkin Stem Cells commentoComments Off on Lab-Grown Stem Cell ‘Mini Brains’ Just Developed Eyes – Interesting Engineering | dataAugust 19th, 2021
Read All

We tried 500 worth of Augustinus Bader skincare to see if it really lives up to the hype – The Independent

By daniellenierenberg

Since its launch in 2018, skincare brand Augustinus Bader has been the It girl of the luxury beauty sphere, with a star-studded fan base thats impossible to ignore.

Founded by a world-renowned stem cell specialist and backed by decades of research, its admirers include the likes of Gigi Hadid, Kim Kardashian, Alexa Chung, Meghan Markle and Jennifer Aniston. Victoria Beckham was such a fan that she decided to collaborate with the brand to create skincare for her own line, VB Beauty.

If you dont trust the opinions of A-listers alone, you may also be interested to know that Augustinus Baders range was recently voted the greatest skincare of all time by a panel of 300 industry experts, beating the likes of La Mer and Estee Lauder to the title. The brand has also just launched an initiative that allows customers to choose a five per cent donation to a charity that matters to them, on every order, which only adds to its impressive credentials.

Ready to shop now? Browse the full Augustinus Bader range at Augustinusbader.com

So what is all the fuss about, we hear you ask? Well, it all boils down to some pretty impressive science. Professor Augustinus Bader, a German-born doctor, scientist and co-founder of the eponymous brand, has dedicated 30 years of his career to researching skin healing and tissue repair. This led to him creating a medical-grade hydrogel that treats the skin of burns victims. After envisioning how the success of this treatment could be applied to commercial skincare, Bader then incorporated the same technology into all of his products, in the form of his patented Trigger Factor Complex, known as TFC8. Still with us?

TFC8 is a cocktail of 40 different ingredients, including vitamins, amino acids and synthesised molecules found naturally in the body. Based on the idea that your body has an innate code for tissue repair, the complex essentially unlocks this code, forcing your skin into healing mode and tackling ageing, damage, scarring and dullness in the process. The brand claims that this technology visibly transforms the skin, and many consumers seem to agree.

But all of this technology comes at a rather eye-watering price, with the brands cult moisturiser costing 205. With this in mind, we spent a month exclusively testing Augustinus Baders products to see if they deliver on these transformative claims.

Were kicking off with the product that secured Augustinus Baders pivot to cult status. Youve almost certainly seen this moisturiser on many a bathroom shelfie its an instantly recognisable bottle that screams luxury straight off the bat. Like everything in the brands skincare line, the cream features the coveted TFC8 complex, and we were keen to see if it lives up to the hype. Regretfully for our bank accounts, we saw near-immediate results after using this cream. Its important to note that we paired the moisturiser with both the brands cleanser and the essence, which also feature TFC8, so our results may have been accelerated, but the cream was our favourite product.

The formula glides onto the skin with ease and absorbs quickly, but theres no luxury scent here (like us, you may prefer this, whether youre sensitive-skinned or more interested in the science). The added radiance is subtle, but the main thing we noticed was how plump our skin looks straight away. The brand describes this as a cushion-y bounce and we couldnt agree more its something weve yet to replicate in the same way from any other skincare product. Longer-term results after a month of use include reduced acne scarring and texture, a more even skin tone and generally healthier-looking skin. It really does feel as though our skin has been regenerated our make-up applied far better on a smoother base and we felt confident with clearer, happier skin.

Despite such technical ingredients, unlike other potent formulas, this is extremely gentle on the skin with no tingling or irritation. On the face of it, it feels like any other moisturiser, but its the results that speak for themselves. You can tell the brand is solely focused on science-backed results as opposed to all the bells and whistles, and were happy with that. The brand also offers a richer version of this moisturiser (205, Augustinusbader.com), and while we found it slightly too heavy for our oily skin, dry skin types will love it.

Housed in a weighty glass jar, the brands cleansing balm is a treat to use. Again, theres practically no scent here, but the buttery balm removes the day with ease. After applying the nourishing formula to dry skin, simply add water to emulsify and watch the balm turn into a milky consistency.

We love how much of a multi-tasker this cleanser is, removing even the heaviest of make-up effortlessly while leaving our skin feeling hydrated and plump. At 55, theres no doubt its an expensive cleanser, but youre paying for the long-term results from the brands regenerative TFC8 technology. Weve tried plenty of cheaper cleansing balms that do the job just as well, but you wont reap the skincare benefits that this one offers.

When paired with the brands other products, our skin was much brighter and clearer. Thankfully, its non-comedogenic too, meaning this is safe to use on acne-prone skin. Despite being great at removing make-up, we did find that we needed to apply quite a lot of the balm to remove it, so given the price, wed suggest using this as a second cleanse to make the most of it.

This toner-chemical-exfoliant-essence hybrid is really putting Augustinus Baders TFC8 complex to work, as the complex formula aims to resurface the skin while balancing it. Unlike other chemical exfoliants, it feels incredibly gentle on the skin with no irritation in sight.

The signature formula triggers the skins renewal processes, essentially forcing it to repair itself. Thanks to this, we noticed reduced acne scarring and redness, and far less texture after just a couple of weeks use. The essence also features gluconolacctone, a poly-hydroxy acid (PHA) that sloughs away dead skin cells, as well as the powerhouse ingredient salicylic acid to tackle congestion and blemishes.

Although using the essence with the brands moisturiser will give you optimum results, if youre stuck between the two, wed plump for this as a starting point for treating skincare concerns such as acne scarring and signs of ageing, as it showcases Baders TFC8 complex in the most potent way.

We cant give our final thoughts without addressing the elephant in the room here: the price. Its without a doubt on the luxury end of the spectrum, but the difficulty is that these products genuinely do work for us, delivering near instant results. There are definitely more affordable products out there that will help you to target acne scarring or dullness with similar success, but the real selling point here is how plump, smooth and seriously revitalised our skin looks after use.

Few skincare products deliver on every marketing promise, but Augustinus Baders do, and if you cant trust a world-leading stem cell scientist then who can you trust. Out of the whole range, wed recommend investing in the essence as a starting point, but if your budget stretches to both, the cream and the essence together make a powerful duo that wed definitely vouch for.

For the latest discounts on skincare and other beauty offers, try the links below:

IndyBest product reviews are unbiased, independent advice you can trust. On some occasions, we earn revenue if you click the links and buy the products, but we never allow this to bias our coverage. The reviews are compiled through a mix of expert opinion and real-world testing.

Originally posted here:
We tried 500 worth of Augustinus Bader skincare to see if it really lives up to the hype - The Independent

To Read More: We tried 500 worth of Augustinus Bader skincare to see if it really lives up to the hype – The Independent
categoriaSkin Stem Cells commentoComments Off on We tried 500 worth of Augustinus Bader skincare to see if it really lives up to the hype – The Independent | dataAugust 19th, 2021
Read All

Adult T-cell leukemia: Types, symptoms, and treatment – Medical News Today

By daniellenierenberg

T-cell leukemia is an uncommon form of cancer that causes a type of white blood cells known as T cells to grow uncontrollably in a persons bone marrow. Adult T-cell leukemia (ATL) is one form of the condition and results from a viral infection.

This information comes from the American Cancer Society.

Experts call the virus that causes ATL human T-cell leukemia virus type-1 (HTLV-1). This virus can also cause a type of lymphoma that begins in the immune system rather than the bone marrow. Doctors refer to the two conditions collectively as adult T-cell leukemia/lymphoma (ATLL).

This article looks at the types, symptoms, and causes of ATL. It also considers the treatment options and survival rates for those with the condition.

T-cell leukemia is a relatively rare form of cancer. Like other types of leukemia, it affects blood-forming cells in the bone marrow. These are cells that will go on to become blood cells but that are still in their early, or immature, form.

In addition to plasma, blood consists of red blood cells, white blood cells, and platelets. These cells go through several stages of development before becoming mature.

T-cell leukemia causes an abnormality in a specific type of immature white blood cells, known as T lymphocytes or T cells. T cells protect the body from infection. If these cells become cancerous, they divide and grow uncontrollably.

ATL is a type of T-cell leukemia caused by HTLV-1. The condition is rare in the United States, but it is more common in Japan, parts of Africa, South America, the Middle East, and the Caribbean.

Most people who contract HTLV-1 do not go on to develop any serious disease. HTLV-1 affects around 10 million people globally, but only 25% of them develop symptomatic ATLL.

There are four subtypes of ATLL:

Learn about the differences between leukemia and lymphoma here.

Symptoms of ATL can vary depending on the subtype a person has. People with the smoldering subtype may not have noticeable symptoms or may only develop a few skin lesions.

People with more aggressive forms of ATL may experience:

Hypercalcemia can be serious. It causes symptoms such as:

Children who develop ATLL often experience the acute or lymphomatous subtypes. Many develop an enlarged thymus, an organ that resides in front of the trachea, or windpipe. This can cause breathing problems.

To diagnose ATLL, a doctor will need to take samples of blood, bone marrow, or tissue. This may involve:

A healthcare professional can take blood from a vein in the arm, whereas bone or bone marrow usually comes from a hip bone.

A specialist will then examine the samples for signs of ATLL using various methods. They may use a microscope to examine them closely, or machines that test the samples proteins and DNA.

It is possible for ATL to go into remission. This means doctors cannot detect ATL in the body, and a person has no symptoms. Remission can be permanent or temporary.

However, ATL is often aggressive. The acute, lymphoma, and unfavorable chronic subtypes are more difficult to treat, while the favorable chronic and smoldering subtypes have a better prognosis.

For slow-growing forms of ATL, doctors may adopt a watch and wait approach to see whether the condition progresses. If the symptoms are mild and do not progress, a person may not need treatment or may not require it for some time.

Around 25% of cases of chronic or smoldering ATLL ultimately progress to the acute form. Anyone with acute ATLL typically undergoes treatment.

First-line treatment for ATL is antiviral therapy. Those with the lymphoma subtype seem to respond better to chemotherapy. Depending on the circumstances, a doctor may recommend one or both approaches.

Some individuals may also receive a stem cell transplantation from a donor, although this combined treatment is still under evaluation for its effectiveness.

Clinical trials are also testing the potential of immunomodulating drugs for ATL treatment.

ATL has a short overall survival rate, even with prompt treatment. This is because ATL is resistant to chemotherapy.

Data from 20002009 show that ATL patients who underwent intensive chemotherapy followed by stem cell transplantation had average survival times of:

Anyone who has completed treatment for ATLL will receive continuous health monitoring as part of their follow-up care. As the time spent in remission increases, these appointments become less frequent.

ATL occurs due to an infection with HTLV-1, a virus that belongs to the same class of viruses as HIV.

Similarly to HIV, HTLV-1 spreads through contact with bodily fluids. It can transmit through:

There is no cure or vaccine for HTLV-1. There is also no consistent method of screening for HTLV-1 worldwide and no way for doctors to predict who will go on to develop ATL. For this reason, preventing its spread is vital for preventing ATL.

However, because most people with HTLV-1 experience no symptoms, this can be challenging. Few studies have looked at the best ways of preventing HTLV-1 transmission.

Approaches that may help include:

Individuals should seek guidance from a doctor if they have any concerning symptoms, such as new rashes, skin lesions, or persistent fatigue.

They should also contact a doctor if they have come into contact with HTLV-1 at any point.

Where possible, schedule regular doctor visits. These give doctors an opportunity to perform physical examinations and obtain blood tests, as necessary. These may pick up on early signs of illness.

Some people with the slow-growing subtypes of T-cell leukemia have no symptoms. For these individuals, it is essential to visit a doctor as soon as any symptoms appear, because this could be a sign of the disease progressing.

ATL is a type of leukemia that affects the bodys T cells, which play a crucial role in the immune system. An HTLV-1 infection causes ATL.

ATL is often aggressive and difficult to treat. Those with a slow-growing subtype, such as smoldering ATL, usually have a better prognosis. The treatment may involve chemotherapy, antiviral drugs, or stem cell transplantation.

Read this article:
Adult T-cell leukemia: Types, symptoms, and treatment - Medical News Today

To Read More: Adult T-cell leukemia: Types, symptoms, and treatment – Medical News Today
categoriaBone Marrow Stem Cells commentoComments Off on Adult T-cell leukemia: Types, symptoms, and treatment – Medical News Today | dataAugust 19th, 2021
Read All

Stem Cell Therapy Market worth $40.3 billion by 2027 Exclusive Report by CoherentMarketInsights – PharmiWeb.com

By daniellenierenberg

The Stem Cell Therapy Market report provides a quick description about market status, size, companies share, growth, opportunities and upcoming trends. This report includes the corporate profile, values that the challenges and drivers & restraints that have a serious impact on the industry analysis. The information within the report that help form the longer term projections during the forecast year. The up so far analysis to assists in understanding of the changing competitive analysis. Additionally, the market strategies including moderate growth during the years.

The research on Stem Cell Therapy market scenario which will affect the overview the forecast period, including as opportunities, prime challenges, and current/future trends. To supply an in-depth analysis of all Stem Cell Therapy regions included within the report into sections to supply a comprehensive competitive analysis.

Get Your Sample Copy of the Stem Cell Therapy Market Report 2021

Some of the leading manufacturers and suppliers of the Stem Cell Therapy market are Magellan, Medipost Co., Ltd, Osiris Therapeutics, Inc., Kolon TissueGene, Inc., JCR Pharmaceuticals Co., Ltd., Anterogen Co. Ltd., Pharmicell Co., Inc., and Stemedica Cell Technologies, Inc.

Stem cells are divided into two major classes; pluripotent and multipotent. Pluripotent stem cells are replicating cells, which are derived from the embryo or fetal tissues. The pluripotent stem cells facilitate the development of cells and tissues in three primary germ layers such as mesoderm, ectoderm, and endoderm.

Market Dynamics

Increasing expansion of facilities by market players for stem cell therapies is expected to propel growth of the stem cell therapy market over the forecast period. For instance, in January 2018, the University of Florida, U.S. launched the Center for Regenerative Medicine that is focused on development of stem cell therapies for the treatment of damaged tissue and organ. The Centre for Regenerative Medicines is divided into two segments such as focus groups and shared services. Focus groups such as research and development activities for stem cell therapies; and the shared services segment offers technical resources related to stem cell therapies.

Furthermore, rising collaboration activities by key players are expected to drive growth of the global stem cell therapy market. For instance, in May 2018, Procella Therapeutics and Smartwise, a medtech company entered into a collaboration with AstraZeneca Pharmaceuticals. Under this collaboration, AstraZeneca utilized Procella Therapeutics stem cell technology for the development of stem cell therapies in cardiovascular diseases. Moreover, in April, 2019, CelluGen Biotech and FamiCord Group collaborated to develop new stem cell-based drugs and advanced medical therapies (ATMP)

What Stem Cell Therapy Market Research Report Covers?

This report covers definition, development, market status, geographical analysis of Stem Cell Therapy market.

Competitor analysis including all the key parameters of Stem Cell Therapy market

Market estimates for at least 7 years

Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and proposals)

Strategic proposals in key business portions dependent available estimations

Company profiling with point by point systems, financials, and ongoing improvements

Mapping of the most recent innovative headways and Supply chain patterns

Buy This Complete A Business Report With Flat US $2000 Off @https://www.coherentmarketinsights.com/promo/buynow/2848

Increasing application of stem cells for the treatment of patients with blood-related cancers, spinal cord injury and other diseases are the leading factors that are expected to drive growth of stem cell therapy market over the forecast period. According to the National Spinal Cord Injury Statistical Center, 2016, the annual incidence of spinal cord injury (SCI) is approximately 54 cases per million population in the U.S. or approximately 17,000 new SCI cases each year.

Moreover, according to the Leukemia and Lymphoma Society, 2017, around 172,910 people in the U.S. were diagnosed with leukemia, lymphoma or myeloma in 2017, thus leading to increasing adoption of stem cells for its efficient treatment. Increasing product launches by key players such as medium for developing embryonic stem cells is expected to propel the market growth over the forecast period.

For instance, in January 2019, STEMCELL Technologies launched mTeSR Plus, a feeder-free human pluripotent stem cell (hPSC) maintenance medium for avoiding conditions associated with DNA damage, genomic instability, and growth arrest in hPSCs. With the launch of mTeSR, the company has expanded its portfolio of mediums for maintenance of human embryonic stem (ES) cells and induced pluripotent stem (iPS) cells. Increasing research and development of induced pluripotent stem cells coupled with clinical trials is expected to boost growth of the stem cell therapy market over the forecast period.

For instance, in April 2019, Fate Therapeutics in collaboration with UC San Diego researchers launched Off-the-shelf immunotherapy (FT500) developed from human induced pluripotent stem cells. The therapy is currently undergoing clinical trials for the treatment of advanced solid tumors.

Ask for PDF sample copy of the Stem Cell Therapy market report

Main points in Stem Cell Therapy Market Report Table of Content

Chapter 1 Industry Overview

1.1 Definition

1.2 Assumptions

1.3 Research Scope

1.4 Market Analysis by Regions

1.5 Global Stem Cell Therapy Market Size Analysis from 2021 to 2027

11.6 COVID-19 Outbreak: Stem Cell Therapy Industry Impact

Chapter 2 Global Stem Cell Therapy Competition by Types, Applications, and Top Regions and Countries

2.1 Global Stem Cell Therapy (Volume and Value) by Type

2.3 Global Stem Cell Therapy (Volume and Value) by Regions

Chapter 3 Production Market Analysis

3.1 Global Production Market Analysis

3.2 Regional Production Market Analysis

Chapter 4 Global Stem Cell Therapy Sales, Consumption, Export, Import by Regions (2016-2021)

Chapter 5 North America Stem Cell Therapy Market Analysis

Chapter 6 East Asia Stem Cell Therapy Market Analysis

Chapter 7 Europe Stem Cell Therapy Market Analysis

Chapter 8 South Asia Stem Cell Therapy Market Analysis

Chapter 9 Southeast Asia Stem Cell Therapy Market Analysis

Chapter 10 Middle East Stem Cell Therapy Market Analysis

Chapter 11 Africa Stem Cell Therapy Market Analysis

Chapter 12 Oceania Stem Cell Therapy Market Analysis

Chapter 13 South America Stem Cell Therapy Market Analysis

Chapter 14 Company Profiles and Key Figures in Stem Cell Therapy Business

Chapter 15 Global Stem Cell Therapy Market Forecast (2021-2027)

Chapter 16 Conclusions

View Press Release For More Information

Related Reports:

Stem Cell Assay Market, By Product Type (Instruments and Reagents & Kits), By Cell Type (Adult Stem Cells and Human Embryonic Stem Cells), By Process (Cell Culture, Engineering, Differentiation, Characterization, and Others), By Application (Research, Drug Discovery & Development, and Regenerative Medicine), and By Region Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2020-2027

Stem Cell Banking Market, by Source Type (Cord Blood and Cord Tissue), by Service Type (Collection and Transportation, Processing, Analysis and Storage), by Application (Leukemia, Diabetes, Lymphoma, Cerebral Palsy, Thalassemia and Others), and by Region Global Trends, and Forecast to 2027

Cell Culture Media for Vaccine Market by Media Type (Bovine Derived, Porcine Derived, and Animal Free/Serum Free Cell Culture), by Application (Human Vaccine and Animal Vaccine), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Size, Share, Outlook, and Opportunity Analysis, 2020-2027

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

Contact:

Coherent Market Insights1001 4th Ave, #3200 Seattle, WA 98154, U.S.Email:sales@coherentmarketinsights.comUnited States of America: +1-206-701-6702United Kingdom: +44-020-8133-4027Japan: +050-5539-1737India: +91-848-285-0837

Read the original post:
Stem Cell Therapy Market worth $40.3 billion by 2027 Exclusive Report by CoherentMarketInsights - PharmiWeb.com

To Read More: Stem Cell Therapy Market worth $40.3 billion by 2027 Exclusive Report by CoherentMarketInsights – PharmiWeb.com
categoriaSpinal Cord Stem Cells commentoComments Off on Stem Cell Therapy Market worth $40.3 billion by 2027 Exclusive Report by CoherentMarketInsights – PharmiWeb.com | dataAugust 19th, 2021
Read All

Regenerative Medicine Market Size Worth $57.08 Billion By 2027: Grand View Research, Inc. – PRNewswire

By daniellenierenberg

SAN FRANCISCO, Aug. 12, 2021 /PRNewswire/ --The global regenerative medicine marketsize is expectedto reach USD 57.08 billion by 2027, growing at a CAGR of 11.27% over the forecast period, according to a new report by Grand View Research, Inc. Recent advancements in biological therapies have resulted in a gradual shift in preference toward personalized medicinal strategies over the conventional treatment approach. This has resulted in rising R&D activities in the regenerative medicine arena for the development of novel regenerative therapies.

Key Insights & Findings:

Read 273 page research report, "Regenerative Medicine Market Size, Share & Trends Analysis Report By Product (Cell-based Immunotherapies, Gene Therapies), By Therapeutic Category (Cardiovascular, Oncology), And Segment Forecasts, 2021 - 2027", by Grand View Research

Furthermore,advancements in cell biology, genomics research, and gene-editing technology are anticipated to fuel the growth of the industry. Stem cell-based regenerative therapies are in clinical trials, which may help restore damaged specialized cells in many serious and fatal diseases, such as cancer, Alzheimer's, neurodegenerative diseases, and spinal cord injuries. For instance, various research institutes have adopted Human Embryonic Stem Cells (hESCs) to develop a treatment for Age-related Macular Degeneration (AMD).

Constant advancements in molecular medicines have led to the development of gene-based therapy, which utilizes targeted delivery of DNA as a medicine to fight against various disorders. Gene therapy developments are high in oncology due to the rising prevalence and genetically driven pathophysiology of cancer. The steady commercial success of gene therapies is expected to accelerate the growth of the global market over the forecast period.

Grand View Research has segmented the global regenerative medicine market on the basis of product, therapeutic category, and region:

List of Key Players of Regenerative Medicine Market

Check out more studies related to Global Biotechnology Industry, conducted by Grand View Research:

Gain access to Grand View Compass, our BI enabled intuitive market research database of 10,000+ reports

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

Contact:Sherry JamesCorporate Sales Specialist, USAGrand View Research, Inc.Phone: 1-415-349-0058Toll Free: 1-888-202-9519Email: [emailprotected]Web: https://www.grandviewresearch.comFollow Us: LinkedIn| Twitter

SOURCE Grand View Research, Inc.

Read more:
Regenerative Medicine Market Size Worth $57.08 Billion By 2027: Grand View Research, Inc. - PRNewswire

To Read More: Regenerative Medicine Market Size Worth $57.08 Billion By 2027: Grand View Research, Inc. – PRNewswire
categoriaSpinal Cord Stem Cells commentoComments Off on Regenerative Medicine Market Size Worth $57.08 Billion By 2027: Grand View Research, Inc. – PRNewswire | dataAugust 19th, 2021
Read All

The prevalence of inorganic mercury in human cells increases during aging but decreases in the very old | Scientific Reports – Nature.com

By daniellenierenberg

Garagnani, P. et al. Whole-genome sequencing analysis of semi-supercentenarians. Elife 10, e57849 (2021).

PubMed PubMed Central Article Google Scholar

Sorrentino, J. A., Sanoff, H. K. & Sharpless, N. E. Defining the toxicology of aging. Trends Mol. Med. 20, 375384 (2014).

CAS PubMed PubMed Central Article Google Scholar

Stohs, S. J. & Bagchi, D. Oxidative mechanisms in the toxicity of metal ions. Free Radic. Biol. Med. 18, 321336 (1995).

CAS PubMed Article PubMed Central Google Scholar

Crespo-Lopez, M. E. et al. Mercury and human genotoxicity: Critical considerations and possible molecular mechanisms. Pharmacol. Res. 60, 212220 (2009).

CAS PubMed Article Google Scholar

Pollard, K. M., Cauvi, D. M., Toomey, C. B., Hultman, P. & Kono, D. H. Mercury-induced inflammation and autoimmunity. Biochim. Biophys. Acta Gen. Subj. 1863, 129299 (2019).

CAS PubMed PubMed Central Article Google Scholar

Kennedy, B. K. et al. Geroscience: Linking aging to chronic disease. Cell 159, 709713 (2014).

CAS PubMed PubMed Central Article Google Scholar

Franceschi, C. et al. The continuum of aging and age-related diseases: Common mechanisms but different rates. Front. Med. (Lausanne) 5, 61 (2018).

Article Google Scholar

Streets, D. G. et al. All-time releases of mercury to the atmosphere from human activities. Environ. Sci. Technol. 45, 1048510491 (2011).

ADS CAS PubMed PubMed Central Article Google Scholar

Clarkson, T. W. & Magos, L. The toxicology of mercury and its chemical compounds. Crit. Rev. Toxicol. 36, 609662 (2006).

CAS PubMed Article Google Scholar

Charleston, J. S. et al. Increases in the number of reactive glia in the visual cortex of Macaca fascicularis following subclinical long-term methyl mercury exposure. Toxicol. Appl. Pharmacol. 129, 196206 (1994).

CAS PubMed Article PubMed Central Google Scholar

Vahter, M. et al. Speciation of mercury in the primate blood and brain following long-term exposure to methyl mercury. Toxicol. Appl. Pharmacol. 124, 221229 (1994).

CAS PubMed Article PubMed Central Google Scholar

Vahter, M. E. et al. Demethylation of methyl mercury in different brain sites of Macaca fascicularis monkeys during long-term subclinical methyl mercury exposure. Toxicol. Appl. Pharmacol. 134, 273284 (1995).

CAS PubMed Article PubMed Central Google Scholar

Teixeira, F. B. et al. Exposure to inorganic mercury causes oxidative stress, cell death, and functional deficits in the motor cortex. Front. Mol. Neurosci. 11, 125 (2018).

PubMed PubMed Central Article CAS Google Scholar

Danscher, G. & Moller-Madsen, B. Silver amplification of mercury sulfide and selenide: A histochemical method for light and electron microscopic localization of mercury in tissue. J. Histochem. Cytochem. 33, 219228 (1985).

CAS PubMed Article PubMed Central Google Scholar

Pamphlett, R., Bishop, D. P., Kum Jew, S. & Doble, P. A. Age-related accumulation of toxic metals in the human locus ceruleus. PLoSOne 13, e0203627 (2018).

PubMed PubMed Central Article CAS Google Scholar

Pamphlett, R., Kum Jew, S., Doble, P. A. & Bishop, D. P. Elemental analysis of aging human pituitary glands implicates mercury as a contributor to the somatopause. Front. Endocrinol. (Lausanne) 10, 419 (2019).

Article Google Scholar

Pamphlett, R., Doble, P. A. & Bishop, D. P. Mercury in the human thyroid gland: Potential implications for thyroid cancer, autoimmune thyroiditis, and hypothyroidism. PLoSOne 16, e0246748 (2021).

CAS PubMed PubMed Central Article Google Scholar

Pamphlett, R., Doble, P. A. & Bishop, D. P. The prevalence of inorganic mercury in human kidneys suggests a role for toxic metals in essential hypertension. Toxics 9, 67 (2021).

PubMed PubMed Central Article Google Scholar

Pamphlett, R., Kum Jew, S., Doble, P. A. & Bishop, D. P. Mercury in the human adrenal medulla could contribute to increased plasma noradrenaline in aging. Sci. Rep. 11, 2961 (2021).

ADS CAS PubMed PubMed Central Article Google Scholar

Pamphlett, R. & Png, F. Y. Shrinkage of motor axons following systemic exposure to inorganic mercury. J. Neuropathol. Exp. Neurol. 57, 360366 (1998).

CAS PubMed Article Google Scholar

Pamphlett, R., Colebatch, A. J., Doble, P. A. & Bishop, D. P. Mercury in pancreatic cells of people with and without pancreatic cancer. Int. J. Environ. Res. Public Health 17, 8990 (2020).

CAS PubMed Central Article PubMed Google Scholar

Chang, A. Y., Skirbekk, V. F., Tyrovolas, S., Kassebaum, N. J. & Dieleman, J. L. Measuring population ageing: An analysis of the Global Burden of Disease Study 2017. Lancet Public Health 4, e159e167 (2019).

PubMed PubMed Central Article Google Scholar

Benarroch, E. E. Locus coeruleus. Cell Tissue Res. 373, 221232 (2018).

PubMed Article Google Scholar

Pamphlett, R. et al. Concentrations of toxic metals and essential trace elements vary among individual neurons in the human locus ceruleus. PLoSOne 15, e0233300 (2020).

CAS PubMed PubMed Central Article Google Scholar

Rudman, D. et al. Effects of human growth hormone in men over 60 years old. N. Engl. J. Med. 323, 16 (1990).

CAS PubMed Article Google Scholar

Seravalle, G. & Grassi, G. Sympathetic nervous system, hypertension, obesity and metabolic syndrome. High Blood Press. Cardiovasc. Prev. 23, 175179 (2016).

CAS PubMed Article Google Scholar

Barbi, E., Lagona, F., Marsili, M., Vaupel, J. W. & Wachter, K. W. The plateau of human mortality: Demography of longevity pioneers. Science 360, 14591461 (2018).

ADS MathSciNet CAS PubMed PubMed Central MATH Article Google Scholar

Gampe, J. Mortality of Supercentenarians: Estimates from the Updated IDL. In Exceptional Lifespans (eds Maier, H., Jeune, B., & Vaupel, J. W.) Ch. 3, 2935 (Springer, 2021).

Holland, D., Desikan, R. S., Dale, A. M. & McEvoy, L. K. Rates of decline in Alzheimer disease decrease with age. PLoSOne 7, e42325 (2012).

ADS CAS PubMed PubMed Central Article Google Scholar

Hirsch, L., Jette, N., Frolkis, A., Steeves, T. & Pringsheim, T. The incidence of Parkinsons disease: A systematic review and meta-analysis. Neuroepidemiology 46, 292300 (2016).

PubMed Article PubMed Central Google Scholar

Logroscino, G. et al. Incidence of amyotrophic lateral sclerosis in Europe. J. Neurol. Neurosurg. Psychiatry 81, 385390 (2010).

PubMed Article PubMed Central Google Scholar

Monnet-Tschudi, F., Zurich, M. G., Boschat, C., Corbaz, A. & Honegger, P. Involvement of environmental mercury and lead in the etiology of neurodegenerative diseases. Rev. Environ. Health 21, 105117 (2006).

CAS PubMed Article PubMed Central Google Scholar

Smith, D. W. Cancer mortality at very old ages. Cancer 77, 13671372 (1996).

CAS PubMed Article PubMed Central Google Scholar

Harding, C., Pompei, F., Lee, E. E. & Wilson, R. Cancer suppression at old age. Cancer Res. 68, 44654478 (2008).

CAS PubMed Article PubMed Central Google Scholar

International Agency for Research on Cancer. Mercury and mercury compounds. IARC Monogr. Eval. Carcinog. Risks Hum. 58, 239345 (1993).

Google Scholar

Nersesyan, A. et al. Results of micronucleus assays with individuals who are occupationally and environmentally exposed to mercury, lead and cadmium. Mutat. Res. 770, 119139 (2016).

CAS Article Google Scholar

Noureldine, S. I. & Tufano, R. P. Association of Hashimotos thyroiditis and thyroid cancer. Curr. Opin. Oncol. 27, 2125 (2015).

PubMed Article PubMed Central Google Scholar

Kim, C. S. et al. Association of hypertension and blood pressure with kidney cancer risk: A nationwide population-based cohort study. Hypertension 75, 14391446 (2020).

CAS PubMed Article PubMed Central Google Scholar

Danscher, G. Light and electron microscopic localization of silver in biological tissue. Histochemistry 71, 177186 (1981).

CAS PubMed Article PubMed Central Google Scholar

Pamphlett, R. & Kum Jew, S. Age-related uptake of heavy metals in human spinal interneurons. PLoSOne 11, e0162260 (2016).

PubMed PubMed Central Article CAS Google Scholar

Pamphlett, R. & Kum Jew, S. Inorganic mercury in human astrocytes, oligodendrocytes, corticomotoneurons and the locus ceruleus: Implications for multiple sclerosis, neurodegenerative disorders and gliomas. Biometals 31, 807819 (2018).

CAS PubMed PubMed Central Article Google Scholar

Pamphlett, R. et al. The distribution of toxic metals in the human retina and optic nerve head: Implications for age-related macular degeneration. PLoSOne 15, e0241054 (2020).

CAS PubMed PubMed Central Article Google Scholar

Pamphlett, R., Kum Jew, S. & Cherepanoff, S. Mercury in the retina and optic nerve following prenatal exposure to mercury vapor. PLoSOne 14, e0220859 (2019).

CAS PubMed PubMed Central Article Google Scholar

Pamphlett, R., Satgunaseelan, L., Kum Jew, S., Doble, P. A. & Bishop, D. P. Elemental bioimaging shows mercury and other toxic metals in normal breast tissue and in breast cancers. PLoSOne 15, e0228226 (2020).

CAS PubMed PubMed Central Article Google Scholar

Pamphlett, R. & Kum Jew, S. Mercury is taken up selectively by cells involved in joint, bone, and connective tissue disorders. Front. Med. (Lausanne) 6, 168 (2019).

Article Google Scholar

Danscher, G., Horsted-Bindslev, P. & Rungby, J. Traces of mercury in organs from primates with amalgam fillings. Exp. Mol. Pathol. 52, 291299 (1990).

CAS PubMed Article PubMed Central Google Scholar

Warfvinge, K. & Bruun, A. Mercury distribution in the squirrel monkey retina after in Utero exposure to mercury vapor. Environ. Res. 83, 102109 (2000).

CAS PubMed Article PubMed Central Google Scholar

Parkin Kullmann, J. A. & Pamphlett, R. A comparison of mercury exposure from seafood consumption and dental amalgam fillings in people with and without amyotrophic lateral sclerosis (ALS): An international online case-control study. Int. J. Environ. Res. Public Health 15, 2874 (2018).

CAS PubMed Central Article Google Scholar

The rest is here:
The prevalence of inorganic mercury in human cells increases during aging but decreases in the very old | Scientific Reports - Nature.com

To Read More: The prevalence of inorganic mercury in human cells increases during aging but decreases in the very old | Scientific Reports – Nature.com
categoriaSpinal Cord Stem Cells commentoComments Off on The prevalence of inorganic mercury in human cells increases during aging but decreases in the very old | Scientific Reports – Nature.com | dataAugust 19th, 2021
Read All

Heat Biologics Announces Formation of Biothreat Advisory Board

By Dr. Matthew Watson

Former Deputy Assistant Secretary of Defense for Countering Weapons of Mass Destruction, David Lasseter, and Former US Representative Jack Kingston, join newly formed Board Former Deputy Assistant Secretary of Defense for Countering Weapons of Mass Destruction, David Lasseter, and Former US Representative Jack Kingston, join newly formed Board

See more here:
Heat Biologics Announces Formation of Biothreat Advisory Board

To Read More: Heat Biologics Announces Formation of Biothreat Advisory Board
categoriaGlobal News Feed commentoComments Off on Heat Biologics Announces Formation of Biothreat Advisory Board | dataAugust 19th, 2021
Read All

Page 21234..1020..»